3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
CNS
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
Breast
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hematologic Diseases
1
Blood Protein Disorders
1
Interventions
Dexamethasone
126
daratumumab
75
Lenalidomide
72
Bortezomib
62
pomalidomide
47
Cyclophosphamide
42
carfilzomib
41
Calcium Dobesilate
36
Specimen Handling
34
Biopsy
30
Magnetic Resonance Spectroscopy
28
belantamab mafodotin
25
fludarabine
21
isatuximab
20
dexamethasone acetate
18
dexamethasone 21-phosphate
18
auricularum
18
Melphalan
18
iberdomide
17
talquetamab
16
fludarabine phosphate
12
selinexor
11
elotuzumab
10
X-Rays
10
tocilizumab
9
Nivolumab
8
Whole-Body Irradiation
7
Sirolimus
7
Crizotinib
7
trametinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
CLR1404
×
Plasma cell
×
90 days
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled